Navigation Links
FSH Society for Muscular Dystrophy is One of “Ten Charities Worth Watching”
Date:5/15/2013

Lexington, MA (PRWEB) May 15, 2013

The Massachusetts-based FSH Society, Inc., has just been ranked among America’s “Ten Charities Worth Watching” by one of the nation’s leading charity watchdog organizations.

According to Charity Navigator, “Many of America's most effective charities are also household names. But some well-known charities are less effective than you'd think, while a number of lesser known charities are truly exceptional.” Among the latter is the FSH Society, a charity founded in 1991 by two patients affected with facioscapulohumeral muscular dystrophy, or FSHD, a genetic disorder striking an estimated 1 in 7,500 to 14,000 people.

The FSH Society’s inclusion in the highly prestigious list was announced on Charity Navigator’s website. “These 10 charities all operate on less than $2 million a year, but they all earn a four-star rating from Charity Navigator,” the website states. “We encourage you to learn more about them.”

FSHD is named for the body areas that are typically affected: the face (facio-), shoulder blades (scapula-) and upper arms (humeral). The disease weakens muscles in these regions, making it difficult to blink or smile, or raise the arms overhead. FSHD can also lay siege to leg, hip and trunk muscles, leading to falls, broken bones and dependence on a scooter or wheelchair. Some patients endure hearing loss.

The FSH Society has received Charity Navigator’s four-star rating for five years in a row, placing it among the top four percent of U.S. charity organizations. The rating indicates that the Society “adheres to good governance and other best practices that minimize the chance of unethical activities and consistently executes its mission in a fiscally responsible way,” Ken Berger, President and CEO of Charity Navigator, wrote in a congratulatory letter addressed to FSH Society President and CEO Daniel Perez.

“Ninety percent of the members of our Board of Directors are personally affected by FSHD, so we care deeply about being accountable to the thousands of patients and families,” said Perez. “We are delighted that we have been recognized for being highly efficient and effective. This exceptional designation from Charity Navigator demonstrates to the public that the Society is worthy of their trust.”

Based on information provided in IRS Form 990, Charity Navigator analyzed FSH Society’s performance in seven financial metrics: program expenses, administrative expenses, fundraising expenses, fundraising efficiency, primary revenue growth, program expenses growth, and working capital ratio. It also evaluated the organization in several accountability and transparency performance metrics, giving the Society an overall rating of 68.5 points out of a maximum score of 70.

Around 500,000 people worldwide have FSHD, and between one and two percent of the population carries a genetic trait that places future generations at risk of FSHD. Funding from the FSH Society paved the way for the recent discovery of the genetic mechanism of the disease.

There is now an intensive global effort to find treatments, and scientists say these breakthroughs in FSHD research could carry over into cancer, diabetes and other illnesses affecting hundreds of millions of people.

Despite the scientific waves that FSHD is making, many physicians remain unfamiliar with the disease, leaving thousands of patients undiagnosed and unaware that there are others who share their plight. In addition to investing in scientific research, the FSH Society offers a community of support, news and information for FSHD patients and families through its website at http://www.fshsociety.org.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10734898.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
3. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
4. Elsevier Collaborates with the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)
5. Monsanto Declared Worst Company of 2011 by NaturalSociety
6. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
7. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
8. Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservations 2nd World Congress
9. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
10. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
11. Society of Interventional Radiology Names Marshall Hicks, M.D., FSIR, as 2012-13 President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company harnessing the ... for triple negative breast cancer (TNBC), announced today their completion ... program. The YEi Start in France ... grow their business in France and ... to complete an intensive one week immersion in ...
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... 2017  Champions Oncology, Inc. (NASDAQ: CSBR ... of advanced technology solutions and products to personalize the ... addition of new cohorts of PDX models to their ... expand Champions, product line in hepatocellular cancer, breast cancer, ... and non-small cell lung cancer (including EGFR mutation; ALK/ROS1 ...
(Date:2/16/2017)... , ... February 16, 2017 ... ... Molecular Research Inc. has further extended its industry leading Biochemistry Services specifically ... offers state-of-the-art cGMP techniques and methods for the biochemical and biosimilar ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
(Date:1/26/2017)...  Crossmatch, a leading provider of security and identity ... combatting fraud, waste and abuse in assistance operations around ... on Disaster Relief conference in Panama City ... and foreign assistance organizations throughout Latin America ... a largely unacknowledged problem in the foreign assistance and ...
Breaking Biology News(10 mins):